Last reviewed · How we verify

FF/UMEC/VI (200/31.25/25) mcg

GlaxoSmithKline · Phase 3 active Small molecule

FF/UMEC/VI (200/31.25/25) mcg is a Triple combination inhaler (ICS/LAMA/LABA) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

FF/UMEC/VI is a triple combination inhaler that relaxes airway smooth muscle and reduces airway inflammation through multiple mechanisms to improve airflow in chronic obstructive pulmonary disease.

FF/UMEC/VI is a triple combination inhaler that relaxes airway smooth muscle and reduces airway inflammation through multiple mechanisms to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Generic nameFF/UMEC/VI (200/31.25/25) mcg
SponsorGlaxoSmithKline
Drug classTriple combination inhaler (ICS/LAMA/LABA)
TargetGlucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhasePhase 3

Mechanism of action

Fluticasone furoate (FF) is an inhaled corticosteroid that reduces airway inflammation. Umeclidinium (UMEC) is a long-acting muscarinic antagonist that relaxes airway smooth muscle. Vilanterol (VI) is a long-acting beta-2 agonist that further relaxes bronchial smooth muscle. Together, these three agents provide complementary bronchodilation and anti-inflammatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about FF/UMEC/VI (200/31.25/25) mcg

What is FF/UMEC/VI (200/31.25/25) mcg?

FF/UMEC/VI (200/31.25/25) mcg is a Triple combination inhaler (ICS/LAMA/LABA) drug developed by GlaxoSmithKline, indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

How does FF/UMEC/VI (200/31.25/25) mcg work?

FF/UMEC/VI is a triple combination inhaler that relaxes airway smooth muscle and reduces airway inflammation through multiple mechanisms to improve airflow in chronic obstructive pulmonary disease.

What is FF/UMEC/VI (200/31.25/25) mcg used for?

FF/UMEC/VI (200/31.25/25) mcg is indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

Who makes FF/UMEC/VI (200/31.25/25) mcg?

FF/UMEC/VI (200/31.25/25) mcg is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is FF/UMEC/VI (200/31.25/25) mcg in?

FF/UMEC/VI (200/31.25/25) mcg belongs to the Triple combination inhaler (ICS/LAMA/LABA) class. See all Triple combination inhaler (ICS/LAMA/LABA) drugs at /class/triple-combination-inhaler-ics-lama-laba.

What development phase is FF/UMEC/VI (200/31.25/25) mcg in?

FF/UMEC/VI (200/31.25/25) mcg is in Phase 3.

What are the side effects of FF/UMEC/VI (200/31.25/25) mcg?

Common side effects of FF/UMEC/VI (200/31.25/25) mcg include Tremor, Headache, Palpitations, Oral candidiasis, Nasopharyngitis.

What does FF/UMEC/VI (200/31.25/25) mcg target?

FF/UMEC/VI (200/31.25/25) mcg targets Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor and is a Triple combination inhaler (ICS/LAMA/LABA).

Related